Condition: Metastatic Castration-Resistant Prostatic Cancer · Sponsor: T.O.A.D. Oncology SA
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
This description comes directly from the study's public registry record.
TOAD Clinical Operations · 41 41 556 64 01 · contact@toadonco.com
Always discuss trial participation with your own doctor first.
| Yale University, Yale Cancer Center | New Haven, Connecticut, United States | Not Yet Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| Institut Bergonié | Bordeaux, France | Recruiting |
| Hôpital Paris Saint Joseph | Paris, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| Vall d'Hebron Institute of Oncology | Barcelona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07258407